Noor Mohammad Noori; Alireza Teimouri; iraj shahramian
Abstract
Background: Dilated cardiomyopathy (DCM) is revealed with the left ventricular dilatation and systolic dysfunction. This study was performed to determine the level of Calcitonin Gene ...
Read More
Background: Dilated cardiomyopathy (DCM) is revealed with the left ventricular dilatation and systolic dysfunction. This study was performed to determine the level of Calcitonin Gene Related Peptide (CGRP) and Brain Natriuretic Peptide (BNP) in children with dilated cardiomyopathy and controls and comparison of these two biomarkers in patients. Materials and Methods: This case-control study was performed from April 2014 to March 2015 on patients with DCM. The levels of BNP and CGRP were measured by ELISA and final amounts of biomarkers were compared with echocardiographic finding.37 DCM patients compared with 30 healthy children selected randomly from those who referred to the hospital for routine checkup. Results: In this study the mean age was 10.567± 5.50 and 12.135 ± 4.626 years for controls and cases, respectively (P=0.321). The majority of echocardiography indices in the left and right heart had different means in case and controls (P<0.05). Means of BNP were 213.814 ± 309.601 and 2.76± 1.013 for case and control groups, respectively (P< 0.001). Means of CGRP were 2.278±1.586 and 1.488±0.501 for case and control groups, respectively (P = 0.001). In the dilated cardiomyopathy children however, no significant relationship was observed between CGRP level and Ross classification, but observed a significant association between Ross classification and BNP (Chi square = 15.85 and P=0.001). Conclusion:The present research was performed on DCM patients and showed that most echocardiographic parameters, mean of CGRP and mean of BNP increased in patients compared to healthy children. The severity of illness based on the Ross classification showed significant and positive correlation with BNP level but not with CGRP. Probably could be concluded that, BNP would be a better biomarker in DCM patients.
